Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Yucheol Cheong, Minjin Kim, Jina Ahn, Hana Oh, Jongkwan Lim, Wonil Chae, Seung Won Yang, Min Seok Kim, Ji Eun Yu, Sanguine Byun, Yo Han Jang, Baik Lin Seong

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have been documented to have irreversible virucidal function, with the possible applicability in the inactivated viral vaccine platform. In a mouse model, the coadministration of epigallocatechin-3-gallate (EGCG) with influenza hemagglutinin (HA) antigens induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge. Adjuvant effects were observed for all types of HA antigens, including recombinant full-length HA and HA1 globular domain, and egg-derived inactivated split influenza vaccines. The combination of alum and EGCG further increased neutralizing (NT) antibody titers with the corresponding hemagglutination inhibition (HI) titers, demonstrating a dose-sparing effect. Remarkably, EGCG induced immunoglobulin isotype switching from IgG1 to IgG2a (approximately >64–700 fold increase), exerting a more balanced TH1/TH2 response compared to alum. The upregulation of IgG2a correlated with significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) function (approximately 14 fold increase), providing a potent effector-mediated protection in addition to NT and HI. As the first report on a novel class of vaccine adjuvants with built-in virucidal activities, the results of this study will help improve the efficacy and safety of vaccines for pandemic preparedness.

Original languageEnglish
Article number769088
JournalFrontiers in Immunology
Volume12
DOIs
Publication statusPublished - 2021 Nov 12

Bibliographical note

Funding Information:
This work was supported in part by Brain Korea 21 (BK21) FOUR program and National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science, ICT and Future Planning), grant number 2020R1A2C1010703.

Publisher Copyright:
Copyright © 2021 Cheong, Kim, Ahn, Oh, Lim, Chae, Yang, Kim, Yu, Byun, Jang and Seong.

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant'. Together they form a unique fingerprint.

Cite this